Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. has demonstrated a notable increase in the probability of success for its pipeline candidates, now at 25%, reflecting a strengthening of durability in their gene therapies, particularly for Hemophilia A. The company's proprietary genome editing technology, which boasts a remarkable improvement in editing efficiency of up to 50 times through optimized small AAV-packagable base editors, positions it favorably within the gene editing landscape. Furthermore, the sustained increase in FVIII expression levels in non-human primates over a period of 16 months enhances the outlook for future clinical developments, particularly with anticipated data updates and an IND filing projected for 2026.

Bears say

Metagenomi Inc. is facing a negative outlook due to potential regulatory hurdles that could hinder the approval of its pipeline candidates, which may adversely affect the company's financial projections and risk-adjusted price estimates. The company reported a net loss of $18.8 million, or $0.51 per share, in its 3Q24 financial results, indicating ongoing financial instability. Additional risks include delays in pipeline advancement, unfavorable clinical data outcomes, and safety concerns related to gene editing, which collectively pose a significant threat to Metagenomi's financial viability and market position.

Metagenomi Inc (MGX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Buy based on their latest research and market trends.

According to 6 analysts, Metagenomi Inc (MGX) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.